Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | ESR1 | P03372 | 3/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.51 |
| ▸ | SHBG | P04278 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.44 |
| ▸ | ESRRG | P62508 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4296416 | 0.87 | LMNA (0.56) | NPC1RAB9AESR1ESR2L3MBTL1 | |
| SCHEMBL1642242 | 0.80 | NPC1 (0.81) | NPC1RAB9AESR1ESR2SHBG | |
| SCHEMBL1245129 | 0.80 | RAB9A (0.58) | NPC1RAB9AHTTLMNAMEN1 | |
| SCHEMBL4287468 | 0.79 | LMNA (0.66) | NPC1SMN1; SMN2HTTLMNACA2 | |
| SCHEMBL12137308 | 0.79 | NPC1 (0.71) | NPC1RAB9AESR1ESR2SHBG | |
| SCHEMBL12637601 | 0.79 | NPC1 (0.71) | NPC1RAB9AESR1ESR2SHBG | |
| SCHEMBL10015178 | 0.78 | CYP19A1 (0.51) | NPC1RAB9AESR1ESR2L3MBTL1 | |
| SCHEMBL1758781 | 0.77 | HTT (0.75) | RAB9AESR1ESR2L3MBTL1SMN1; SMN2 | |
| SCHEMBL5186624 | 0.77 | ALDH1A1 (0.54) | ESR1ESR2L3MBTL1SMN1; SMN2HTT | |
| SCHEMBL1259916 | 0.77 | ESRRG (0.46) | NPC1RAB9AESR1ESR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7601855-B2 | anticancer agents; chemotherapeutic selective agents | NOVOGEN RESEARCH PTY LTD (AU) | 2009-10-13 | — | — | US | disclosed |
| US-20060074127-A1 | anticancer agents; chemotherapeutic selective agents | NOVOGEN RESEARCH PTY LTD | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074127-A1 | anticancer agents; chemotherapeutic selective agents | MCL1, TOP2A, TP53 | NPC1 1557/4885RAB9A 1393/4885ESR1 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.